6th World Congress on Targeting Microbiota 2018
Towards Clinical Revolution

AGENDA
October 28 - 30, 2018
Porto, Portugal

www.microbiota-site.com
### Congress Sessions:
- Microbiota 2018: recent advances & challenges
- Recent analysis, methods, bioinformatics & interpretations
- Strategic role of metabolites and mediators on the microbiota-host cross-talk
- Strategies to manipulate microbiota & medicine of tomorrow

### Key dates
- **Friday, Oct. 12, 2018**: Registration
- **Wednesday, Oct. 17, 2018**: Poster Submission

### Microbiota 2018 Speakers

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yurdagul Zopf</td>
<td>Recent advances on gut microbiota and food intolerances</td>
<td>University of Erlangen-Nuremberg, Germany</td>
</tr>
<tr>
<td>Paul Forsythe</td>
<td>Psycho neuro immunology and gut microbes</td>
<td>McMaster University, Canada</td>
</tr>
<tr>
<td>Jan Mazala</td>
<td>Targeted gut microbiota and short chain fatty acid profile among term and preterm infants</td>
<td>Poznan University of Medical Sciences, Poland</td>
</tr>
<tr>
<td>Markus Egert</td>
<td>Honor thy lodgers? Interactions between the built environment microbiome and the human microbiome</td>
<td>Furtwangen University, Germany</td>
</tr>
<tr>
<td>Mohammadali Khan Mirzaei</td>
<td>Phage therapy strategy to modulate the child stunting microbiota</td>
<td>McGill University, Canada</td>
</tr>
<tr>
<td>Julien Diana</td>
<td>Crosstalk between gut microbiota, innate immune cells and endocrine cells in the pancreas regulates autoimmune diabetes</td>
<td>Inserm, France</td>
</tr>
<tr>
<td>Maria Cecilia Ulron</td>
<td>Recent advances on the relation between the microbiome-gut-brain axis and the neurodegenerative diseases</td>
<td>University of Padova, Italy</td>
</tr>
<tr>
<td>Natalia Beloborodova</td>
<td>Sepsis and Microbiota: Obstacles, Recent Advances and strategies</td>
<td>Negovsky Research Institute, Russia</td>
</tr>
<tr>
<td>David Dungan</td>
<td>Exploring the role of gut dysbiosis in neuroinflammation and hypertension</td>
<td>Baylor College of Medicine, USA</td>
</tr>
<tr>
<td>Maria Veheesch</td>
<td>Impact of antibiotic treatment on the human microbiota - a review of the clinical implications</td>
<td>University Hospital of Cologne, Germany</td>
</tr>
<tr>
<td>Ernst Hollier</td>
<td>Role of microbes in stem cells transplantation related complication</td>
<td>University Hospital Regensburg, Germany</td>
</tr>
<tr>
<td>Antonio Riva</td>
<td>MAIT cells (Mucosal-Associated Invariant T cells) in liver disease and antibacterial response</td>
<td>Institute of Hepatology London, United Kingdom</td>
</tr>
<tr>
<td>Marcin Ufnal</td>
<td>The effect of gut bacterial metabolites on cardiovascular risk</td>
<td>Medical University of Warsaw, Poland</td>
</tr>
<tr>
<td>Philippe Gerard</td>
<td>Using germfree animal models to prove the role of the gut microbiota in liver diseases</td>
<td>Inra, France</td>
</tr>
<tr>
<td>Cenac Nicolas</td>
<td>Link between microbiota &amp; visceral pain: role of bioactive lipids</td>
<td>Inserm, France</td>
</tr>
<tr>
<td>Kenneth P. Wright</td>
<td>Individual Differences in the Microbiome and Metabolome During Circadian Misalignment and Sleep Restriction: Associations with the Ability to Maintain Wakefulness</td>
<td>University of Colorado Boulder, USA</td>
</tr>
</tbody>
</table>
Dear Colleagues,

On behalf of the International Society of Microbiota, we are pleased to inform you that the 6th World Congress on Targeting Microbiota will be organized at Porto, Portugal, on October 28-30, 2018.

During both days, many oral and poster communications will be presented and will cover many hot topics:

- Microbiota 2018: Recent Advances & Perspectives
- Challenges of microbiota sequencing and analyzing: How to manage the Big Data of sequencing?
- Challenges of microbiota-host cross-talk understanding and intestinal microbiome signaling to extraintestinal organs
- Microbiota & medicine of tomorrow: Development of effective therapeutic strategies to manipulate the gut microbiota

During Targeting Microbiota 2018, we will try to answer many questions, among them:

- Can we modulate the quality and diversity of human microbiota?
- How to induce durable beneficial changes in gut microbiota?
- Where is the red line of the gut microbiota manipulation?
- What are the strategic mediators of gut microbiota?
- How to understand better the role of bacterial metabolites?
- What is the perfect microbiota "signature" and how to use it as a biomarker to "predict" and/or treat many diseases?
- What is the influence of gut microbiota on the development and progression of chronic diseases?

I do believe that this would be the best future strategy for the 6th World Congress of Targeting Microbiota in 2018: a strong communication between basic, pre-clinical scientists and clinicians.

Microbiota & Medicine of Tomorrow: The Revolution

The scientific committee of ISM and in particular Prof. Marvin Edeas (Institut Cochin, Université Paris Descartes, France), founder of the International Society of Microbiota (ISM) wish to highlight: "...there is a deep transformation in our current medicine where big data and Artificial Intelligence will play a strategic role in the medicine of tomorrow. How all big data generated by microbiota sequencing can be used? Can we talk about Artificial Intelligence and microbiota medicine? We wish to open the door for this kind of discussion..."

So, I hope to meet you at the next meeting in order to capture moments of relationship and scientific inspirations by the many and best scientists we have in the world studying the various aspects of the microbiota.

We very much look forward to seeing you in Berlin for this exciting event

Prof. Peter C. Konturek - President of ISM
Teaching Hospital of the University of Jena, Germany
President of the International Society of Microbiota
Scientific Agenda

Chairpersons:
Peter Konturek, Marvin Edesas, Knut Rudi, Markus Egert, Ernst Holler, Jan Mazela, Julien Diana, Paul Forsyth, Roberto Pacifici, Nicolas Cenac, Maria Vehreschild

Day 1 – Sunday, October 28

17h00 – 18h00 Registration – Badges & Material Providing

Day 2 – Monday, October 29

7h45 Welcoming & registration of attendees

8h50 Introduction note by the President of ISM Targeting Microbiota 2018, Prof. Peter Konturek

Session 1: Microbiota 2018: Recent Advances & Challenges
Chairs: Marvin Edesas, Peter Konturek

9h00 Honor the lodgers? – Interaction between the built environment microbiome and the human microbiome (Skin & Gut)
Markus Egert, Furtwangen University, Germany

9h25 Impact of antibiotics and microbiota: recent scientific advances and perspectives
Maria Vehreschild, University Hospital of Cologne, Germany

9h50 Recent advances on gut microbiota and food intolerances
Yurdagül Zopf, University of Erlangen-Nuremberg, Germany

10h15 Exploring the role of gut dysbiosis in neuroinflammation and hypertension
David Durgan, Baylor College of Medicine, USA

10h40 Coffee Break, Network, Exhibition & Poster Session
Chair: Julien Diana

11h20 Link between microbiota & visceral pain: role of bioactive lipids
Nicolas Cenac, Inserm, CHU Purpan, France

11h45 Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain
Francesca Guida, Università degli Studi della Campania “Luigi Vanvitelli”, Italy

11h55 Role of microbes in stem cells transplantation related complication
Ernst Holler, University Hospital Regensburg, Germany

12h20 Enteric microbiome markers as early predictors of clinical outcome in allogeneic hematopoietic stem cell transplant
Nicasio Mancini, University Vita-Salute San Raffaele, Italy

12h30 Metagenomic studies on gut microbial diversity in healthy controls and patients with Entamoeba histolytica infections from New Delhi
Lakshmi Rani Iyer, Jawaharl Nehru University, New Delhi, India

12h40 Lunch Break, Network, Exhibition & Poster Session
## Session 2: Strategies to manipulate microbiota & medicine of tomorrow

**Chairs:** Markus Egert, Peter Konturek

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14h00</td>
<td>Fecal Microbiota Transplant 2018: What’s next?</td>
<td>Peter Konturek, Teaching Hospital of the University of Jena, Germany</td>
</tr>
<tr>
<td>14h25</td>
<td>Phage Therapy strategy to modulate the child stunting microbiota</td>
<td>Mohammadali Khan Mirzaei, McGill University, Canada</td>
</tr>
<tr>
<td>14h50</td>
<td>Probiotic supplementation and associated infant gut microbiome and health: a cautionary retrospective clinical comparison</td>
<td>Candice Quin, University of British Columbia, Canada</td>
</tr>
<tr>
<td>15h00</td>
<td>Fermented milk by <em>Lactobacillus Delbrueckii</em> CIDCA 133 is able to ameliorate the chemotherapy-induced intestinal mucositis in Balb/c mice</td>
<td>Mariana Martins Drumond, Universidade Federal de Minas Gerais, Brazil</td>
</tr>
<tr>
<td>15h10</td>
<td>Microbiota “friendly” lipid nanoparticles to counteract the gastric infection burden</td>
<td>Catarina Leal Seabra, University of Porto, Portugal</td>
</tr>
<tr>
<td>15h20</td>
<td>Curative properties of three probiotics strains in a mice model of cow-milk allergy: impact on T-helper responses</td>
<td>Nathalie Ebner, University of Paris Descartes, France</td>
</tr>
<tr>
<td>15h30</td>
<td>A new freeze-dried formulation to conserve stools over 12 months for fecal transplantation</td>
<td>Julie Reygner, Université Paris Descartes - Faculté de Pharmacie, France</td>
</tr>
<tr>
<td>15h40</td>
<td>Anaerobic cultivated human intestinal microbiota – ACHIM a way to restore intestinal microbiota functions in IBS patients</td>
<td>Elizabeth Norin, Karolinska Institutet, Sweden</td>
</tr>
<tr>
<td>15h50</td>
<td>IL-33 induced by dysbiosis in vaginal microbiota contributes to impaired antiviral immunity against herpes simples virus infection to vaginal mucosa</td>
<td>Heung Kyu Lee, Korea Advanced Institute of Science and Technology, Korea</td>
</tr>
<tr>
<td>16h00</td>
<td>Bacterial quorum sensing molecules manipulate host satiety pathway</td>
<td>Paola Brun, University of Padova, Italy</td>
</tr>
</tbody>
</table>

### Coffee Break, Network, Exhibition & Poster Session

#### Session 3: Microbiota sequencing, big data interpretation, and artificial intelligence: myth or reality?

**Chair:** Yasubumi Sakakibara

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16h50</td>
<td>Microbiota sequencing, big data interpretation, and artificial intelligence: myth or reality?</td>
<td>The aim of this discussion is to connect all the key actors involved in microbiota assessment and analysis: mathematician, computer scientists, bioinformatician, clinician, academics and industrials in order to initiate the discussion about sequencing, big data generating and how to integrate artificial intelligence into microbiota analysis interpretation. Introduction – Metagenome analysis and bioinformatics method for metagenome assembly: recent advances and perspectives</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Development of meta-transcriptome analysis method and its application to meta-transcriptome map of common marmoset</td>
</tr>
<tr>
<td>17h15</td>
<td>A preliminary study on bioinformatics probiotic database for microbiota</td>
<td>Melike Yilmaz, Izmir Institute of Technology, Turkey</td>
</tr>
<tr>
<td>17h25</td>
<td>Electron-microscopic analysis of skin bacterial microbiota in patients with atopic dermatitis and in healthy human hosts</td>
<td>Oksaba V. Rybalchenko, St Petersburg State University, Russian Federation</td>
</tr>
<tr>
<td>17h35</td>
<td>Improving the accuracy and reproducibility of microbiome measurements across labs</td>
<td>Thomas Kuri, Zymo Research GmbH, Freiburg, Germany</td>
</tr>
</tbody>
</table>
International Society of Microbiota

17h45  Point of view of DNA Genotek
       DNA Genotek, Canada

18h05  Genomics solutions that enhance and accelerate microbiota analysis
       Mette K. Lund, Eurofins Genomics, Denmark

18h15  Assessing gut microbiota-host crosstalk: development of a standardized and quantitative targeted metabolomics
       Carlos Malpica, MLP Vision Biotech SL, Spain

18h25  Identification of bacterial taxa with a potential role in Parkinson’s disease using illumine MiSeq and Ion Torrent PGM next generation sequencing
       Severin Weis, Furtwangen University, Germany

18h35  Discussion

18h45  End of the day

20h30  Targeting Microbiota Dinner

Day 3 – Tuesday, October 30

8h25  Opening of the second day

Session 4: Strategic role of metabolites and mediators on the microbiota-host cross-talk

Chair: Knut Rudi

8h30  Microbiota and mitochondria inter-talk in hemodialysis patients: a pilot study
       Marvin Edeas, Université Paris Descartes, Institut Cochin, France

8h55  Crosstalk between gut microbiota, innate immune cells and endocrine cells in the pancreas regulates autoimmune diabetes
       Julien Diana, Institut National de la Santé et de la Recherche Médicale (INSERM), France

9h20  MAIT cells (Mucosal-Associated Invariant T cells) in liver disease and antibacterial response
       Antonio Riva, Institute of Hepatology London, Foundation for Liver Research, United Kingdom

9h45  The effect of gut bacterial metabolites on cardiovascular risk
       Marcin Ufnal, Medical University of Warsaw, Poland

10h10  The triple interaction diet-microbiome-epigenome: a novel approach to type 1 diabetes
       Annalisa Terranegra, Sidra Medicine, Qatar

10h20  Examining the relationship between maternal body size, gestational glucose tolerance, mode of delivery and ethnicity on human milk microbiota at 3 months post-partum
       Lauren Lemay-Nedjelski, University of Toronto, Canada

10h30  Coffee Break, Network, Exhibition & Poster Session

       Chair: Ernst Holler

11h15  Targeted gut microbiota and short chain fatty acid profile among term and preterm infants
       Jan Mazela, Poznan University of Medical Sciences, Poland

11h40  Psycho neuro immunology and gut microbes
       Paul Forsythe, McMaster University, Canada

12h05  Using germfree animal models to prove the role of the gut microbiota in liver diseases
       Philippe Gérard, INRA, France

12h30  Gut microbiota from infant with cow’s milk allergy leads to atopic orientation in a murine model of CMA
       Aurélie Mauras, Université Paris Descartes, France

12h40  Lunch Break, Network, Exhibition & Poster Session
International Society of Microbiota

Chair: Jan Mazela

13h45  Recent advances on the relation between the microbiome-gut-brain axis and the neurodegenerative diseases
Maria Cecilia Giron, University of Padova, Italy

14h10  Individual differences in the microbiome and metabolome during circadian misalignment and sleep restriction: associations with the ability to maintain wakefulness
Kenneth Wright, University of Colorado Boulder, USA

14h35  Sepsis and microbiota: Obstacles, recent advances and strategies
Natalia Beloborodova, Negovsky Research Institute of General Reanimatology, Russia

15h00  Prevalence of akkermansia muciniphila, bacteroides vulgatus and methanobrevibacter smithii in the gut microbiota from relapsing-remitting multiple sclerosis patients
Gislane Lelis Vilela de Oliveira, Barretos School of Health Sciences Dr. Paulo Prata, Brazil

15h25  Current and new approaches for measuring gut-blood barrier permeability
Kinga Jaworska, Medical University of Warsaw, Poland

15h35  Coffee Break, Network, Exhibition & Poster Session

Chairs: Nicolas Cenac, Paul Forsyth

16h05  Interventional strategies binding the human blood microbiota with the states of health, latent and active tuberculosis
Stefan Panaiotov, National Center of Infectious and Parasitic Diseases, Bulgaria

16h15  Delayed liver regeneration in germ-free mice is normalized following colonization with conventional mouse microbiota
Antony M. Wheatley, National University of Ireland, Ireland

16h25  Influence of nutrition and physical activity on bacterial composition in obese patients
Dejan Reljic, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany

16h35  Gut dysbiosis and altered barrier function precedes the appearance of metabolic syndrome in a rat model of maternal food-restriction
Paula Martinez-Oca, University Complutense of Madrid, Spain

16h45  Bile acids, MAIT cell activity and inflammatory parameters and the link to weight in 15 years old children
Anne Mendler, Helmholtz Center for Environmental Research Leipzig, Germany

16h55  Akkermansia Muciniphila ameliorates inflammatory bowel disease via improvement of gut tight junction and epithelial cell ER stress
Qiaozhu Su, Queen’s University Belfast, United Kingdom

17h05  Is skeletal muscle remodeling associated with gut microbiota signature?
Maxence Jollet, University Montpellier, INRA, France

17h15  Evaluation of the effect of the oral consumption of capsules containing Lactobacillus Paracasei LPC-S01 on the vaginal microbiota of healthy adult women: A randomized, placebo-controlled, double-blind, crossover pilot trial
Valentina Taverniti, Università degli Studi di Milano, Italy

17h25  Intestinal Microbiota as a risk for antimicrobial resistance spread – health and ecological threat
Helena Neto Ferreira, University of Porto, Portugal

17h35  General discussion & Concluding remarks
Among of questions which will be discussed:
- Microbiota 2018: Marketing, Claims & Regulations - Bridging the gap between Marketing Strategy and Science
- Microbiota & Medicine of tomorrow: Can we speculate?

Targeting Microbiota 2018 Awards

17h55  End of Targeting Microbiota 2018